Soluble ST2 and Galectin-3 and Progression of CKD

@inproceedings{Alam2019SolubleSA,
  title={Soluble ST2 and Galectin-3 and Progression of CKD},
  author={Mariam L. Alam and Ronit Ben-Abraham Katz and Keith A. Bellovich and Zeenat Yousuf Bhat and Frank C. Brosius and Ian H de Boer and Crystal Ann Gadegbeku and Debbie S. Gipson and Jennifer J. Hawkins and Jonathan Himmelfarb and Bryan R Kestenbaum and Matthias Kretzler and Cassianne Robinson-Cohen and Susan P. Steigerwalt and Courtney Tuegel and Nisha Bansal},
  booktitle={Kidney international reports},
  year={2019}
}
Introduction Cardiac biomarkers soluble ST2 (sST2) and galectin-3 may reflect cardiac inflammation and fibrosis. It is plausible that these mechanisms may also contribute to the progression of kidney disease. We examined associations of sST2 and galectin-3 with kidney function decline in participants with chronic kidney disease (CKD). Methods This was a pooled analysis of 2 longitudinal cohorts of participants with CKD: the Clinical Phenotyping and Resource Biobank (C-PROBE) study and the… CONTINUE READING
BETA
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 63 REFERENCES

Growth Differentiation Factor-15 and Risk of CKD Progression.

  • Journal of the American Society of Nephrology : JASN
  • 2017
VIEW 2 EXCERPTS

Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS).

  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2016
VIEW 3 EXCERPTS

Similar Papers

Loading similar papers…